A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

被引：14
|
作者：
Kulasekararaj, Austin [1 ,2 ]
Risitano, Antonio M. [3 ]
Maciejewski, Jaroslaw P. [4 ]
Notaro, Rosario [5 ,6 ]
Browett, Peter [7 ]
Lee, Jong-Wook [8 ]
Huang, Mingjun [9 ]
Geffner, Michael [10 ]
Brodsky, Robert A. [11 ]
机构：
[1] Kings Coll Hosp London, Dept Haematol, London, England
[2] Kings Collge London, London, England
[3] Univ Naples Federico II, Naples, Italy
[4] Cleveland Clin Fdn, Dept Translat Hematol & Oncol Res, Taussig Canc Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA
[5] Azienda Osped Univ Careggi, Florence, Italy
[6] Inst Studio Prevenz & Rete Oncol, Florence, Italy
[7] Univ Auckland, Dept Mol Med & Pathol, Sch Med, Auckland, New Zealand
[8] Catholic Univ Korea, Dept Hematol, Seoul St Marys Hosp, Seoul, South Korea
[9] Achillion Pharmaceut Inc, New Haven, CT USA
[10] Achillion Pharmaceut Inc, Blue Bell, PA USA
[11] Johns Hopkins Univ, Dept Med, Div Hematol, Baltimore, MD USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124748
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3514
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3 active-comparator, controlled trial
    de Latour, Regis Peffault
    Szer, Jeff
    Weitz, Ilene C.
    Roth, Alexander
    Hochsmann, Britta
    Panse, Jens
    Usuki, Kensuke
    Griffin, Morag
    Kiladjian, Jean-Jacques
    de Castro, Carlos M.
    Nishimori, Hisakazu
    Ajayi, Temitayo
    Al-Adhami, Mohammed
    Deschatelets, Pascal
    Francois, Cedric
    Grossi, Federico
    Risitano, Antonio M.
    Hillmen, Peter
    LANCET HAEMATOLOGY, 2022, 9 (09): : E648 - E659
  • [42] Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the Urothelium who have experienced failure with standard chemotherapy
    Lassiter, Lance K.
    Tummala, Mohan K.
    Hussain, Maha H.
    Stadler, Walter M.
    Petrylak, Daniel P.
    Carducci, Michael A.
    CLINICAL GENITOURINARY CANCER, 2008, 6 (01) : 31 - 35
  • [43] A phase 2, open-label study of bintrafusp alfa monotherapy in patients with HMGA2-expressing triple-negative breast cancer
    Emens, Leisha A.
    Gatti-Mays, Margaret E.
    O'Shaughnessy, Joyce
    Dirix, Luc
    Faggioni, Giovanni
    Fontana, Andrea
    Martin-Babau, Jerome
    Helwig, Christoph
    Huang, Alice
    Iadevaia, Riham
    Ojalvo, Laureen S.
    CANCER RESEARCH, 2021, 81 (04)
  • [44] Oral therapy with the complement factor B inhibitor iptacopan increases hemoglobin concentration and relieves fatigue symptoms in complement inhibitor-naive adults with paroxysmal nocturnal hemoglobinuria: Results of the single-arm, open-label, multicenter phase III APPOINT-PNH study
    Roth, A.
    Risitano, A. M.
    Han, B.
    Ueda, Y.
    Fu, R.
    Li, Z.
    Kulasekararaj, A.
    Jang, J. Ho
    Ping, C. Lee
    Panse, J.
    Yap, E. -S.
    Marano, L.
    de Fontbrune, F. Sicre
    Yang, C.
    Banerjee, P.
    Wang, Z.
    Thorburn, C.
    Li, S.
    Dahlke, M.
    de Latour, Peffault R.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 45 - 45
  • [45] A multicenter, open-label, phase 2 study of Imprime PGG and pembrolizumab in patients with metastatic breast cancer who have progressed through prior hormonal therapy
    Stopeck, Alison
    Gargano, Michele
    Bose, Nandita
    Niles, Nick
    Chisamore, Michael
    Iglesias, Jose
    CANCER RESEARCH, 2022, 82 (04)
  • [46] Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: An open-label, uncontrolled study
    Kaplan, EM
    CLINICAL THERAPEUTICS, 2002, 24 (07) : 1194 - 1200
  • [47] Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study
    Cao, Xin-Xin
    Jin, Jie
    Fu, Cheng-Cheng
    Yi, Shu-Hua
    Zhao, Wei-Li
    Sun, Zi-Min
    Yang, Wei
    Li, Deng-Ju
    Cui, Guo-Hui
    Hu, Jian-da
    Liu, Ting
    Song, Yong-Ping
    Xu, Bing
    Zhu, Zun-Min
    Xu, Wei
    Zhang, Ming-Zhi
    Tian, Ya-Min
    Zhang, Bin
    Zhao, Ren-Bin
    Zhou, Dao-Bin
    ECLINICALMEDICINE, 2022, 52
  • [48] Olaparib monotherapy in patients with advanced cancer and a germ-line BRAC1/2 mutation: An open-label phase II study
    Kaufman, Bella
    Shapira-Frommer, Ronnie
    Schmutzler, Rita K.
    Audeh, M. William
    Friedlander, Michael
    Balmana, Judith
    Mitchell, Gillian
    Fried, Georgeta
    Bowen, Karin
    Fielding, Anitra
    Domchek, Susan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response—a prospective open-label study
    Naoki Hashimoto
    Atsuhito Toyomaki
    Minoru Honda
    Satoru Miyano
    Nobuyuki Nitta
    Hiroyuki Sawayama
    Yasufumi Sugawara
    Keiichi Uemura
    Noriko Tsukamoto
    Tsukasa Koyama
    Ichiro Kusumi
    Annals of General Psychiatry, 14
  • [50] A multicenter, open-label, phase 2 study of odetiglucan (IMPRIME PGG) and pembrolizumab in patients with metastatic breast cancer (mBCA) who have progressed through prior hormonal therapy
    Stopeck, Alison
    Gargano, Michele Anne
    Niles, Nick
    Rathmann, Blaine
    Chisamore, Michael Jon
    Bose, Nandita
    Iglesias, Jose Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345